These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30146961)

  • 21. What are the economic barriers of antibiotic R&D and how can we overcome them?
    Renwick M; Mossialos E
    Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625
    [No Abstract]   [Full Text] [Related]  

  • 22. [Lack of incentives for the development of innovative antibiotics-analysis of market and time constraints].
    Müller R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2020 Jun; 63(6):771-776. PubMed ID: 32410054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibiotic development: a victim of market forces?
    Tillotson GS
    IDrugs; 2008 May; 11(5):340-6. PubMed ID: 18465675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance.
    Sciarretta K; Røttingen JA; Opalska A; Van Hengel AJ; Larsen J
    Clin Infect Dis; 2016 Dec; 63(11):1470-1474. PubMed ID: 27578820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Financing Pull Mechanisms for Antibiotic-Related Innovation: Opportunities for Europe.
    Årdal C; Lacotte Y; Ploy MC
    Clin Infect Dis; 2020 Nov; 71(8):1994-1999. PubMed ID: 32060511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decline in economic returns from new drugs raises questions about sustaining innovations.
    Berndt ER; Nass D; Kleinrock M; Aitken M
    Health Aff (Millwood); 2015 Feb; 34(2):245-52. PubMed ID: 25646104
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Torching the Haystack: modelling fast-fail strategies in drug development.
    Lendrem DW; Lendrem BC
    Drug Discov Today; 2013 Apr; 18(7-8):331-6. PubMed ID: 23246516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery research: the scientific challenge of finding new antibiotics.
    Livermore DM;
    J Antimicrob Chemother; 2011 Sep; 66(9):1941-4. PubMed ID: 21700626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
    Prasad V; Mailankody S
    JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Healthy pharmaceutical policy].
    González Pier E
    Salud Publica Mex; 2008; 50 Suppl 4():S488-95. PubMed ID: 19082260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microcap pharmaceutical firms: linking drug pipelines to market value.
    Beach R
    J Health Care Finance; 2012; 39(2):82-92. PubMed ID: 23971143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re-Inventing Infectious Disease: Antibiotic Resistance and Drug Development at the Bayer Company 1945-80.
    Gradmann C
    Med Hist; 2016 Apr; 60(2):155-80. PubMed ID: 26971595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Innovation in the pharmaceutical industry: New estimates of R&D costs.
    DiMasi JA; Grabowski HG; Hansen RW
    J Health Econ; 2016 May; 47():20-33. PubMed ID: 26928437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Corporate colonization of health activism? Irish health advocacy organizations' modes of engagement with pharmaceutical corporations.
    O'Donovan O
    Int J Health Serv; 2007; 37(4):711-33. PubMed ID: 18072317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ReRouting biomedical innovation: observations from a mapping of the alternative research and development (R&D) landscape.
    Greenberg A; Kiddell-Monroe R
    Global Health; 2016 Sep; 12(1):54. PubMed ID: 27627882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel approaches are needed to develop tomorrow's antibacterial therapies.
    Spellberg B; Bartlett J; Wunderink R; Gilbert DN
    Am J Respir Crit Care Med; 2015 Jan; 191(2):135-40. PubMed ID: 25590154
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Developing the latest framework to measure and incentivise pharmaceutical industry contributions to health research and development.
    Cole CB; Trolle S; Edwards DJ
    Health Res Policy Syst; 2018 Aug; 16(1):73. PubMed ID: 30071858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perspectives on stimulating industrial research and development for neglected infectious diseases.
    Webber D; Kremer M
    Bull World Health Organ; 2001; 79(8):735-41. PubMed ID: 11545330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An assessment of R&D productivity in the pharmaceutical industry.
    Dimitri N
    Trends Pharmacol Sci; 2011 Dec; 32(12):683-5. PubMed ID: 22030299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Public funding of clinical-stage antibiotic development in the United States and European Union.
    Eichberg MJ
    Health Secur; 2015; 13(3):156-65. PubMed ID: 26042859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.